Xin, Lei Tan, Yanli Zhu, Yuanxue Cui, Xiaoteng Wang, Qixue Zhao, Jixing Tian, Shaohui Xu, Can Xiao, Menglin Hong, Biao
...
Published in
Neuro-oncology
Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) has been limited by resistance. The level of O-6-methylguanine-DNA methyltransferase (MGMT) and intrinsic DNA damage repair factors are important for the TMZ response in patients. Here, we reported a novel compound, called EPIC-0307, that increased TMZ sensitivity by inhibiting specific DN...
Bailleul, Justine Ruan, Yangjingyi Abdulrahman, Lobna Scott, Andrew J Yazal, Taha Sung, David Park, Keunseok Hoang, Hanna Nathaniel, Juan Chu, Fang-I
...
Published in
Neuro-oncology
Resistance to existing therapies is a significant challenge in improving outcomes for glioblastoma (GBM) patients. Metabolic plasticity has emerged as an important contributor to therapy resistance, including radiation therapy (RT). Here, we investigated how GBM cells reprogram their glucose metabolism in response to RT to promote radiation resista...
Burger, Michael C Forster, Marie-Therese Romanski, Annette Straßheimer, Florian Macas, Jadranka Zeiner, Pia S Steidl, Eike Herkt, Stefanie Weber, Katharina J Schupp, Jonathan
...
Published in
Neuro-oncology
Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting HER2, which is expressed at elevated levels by a subset of gliobl...
Larsson, Alex T Bhatia, Himanshi Calizo, Ana Pollard, Kai Zhang, Xiaochun Conniff, Eric Tibbitts, Justin F Rono, Elizabeth Cummins, Katherine Osum, Sara H
...
Published in
Neuro-oncology
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that often develop in patients with neurofibromatosis type 1 (NF1). To address the critical need for novel therapeutics in MPNST, we aimed to establish an ex vivo 3D platform that accurately captured the genomic diversity of MPNST and could be utilized in a medium-...
Hardin, Emily C Schmid, Simone Sommerkamp, Alexander Bodden, Carina Heipertz, Anna-Elisa Sievers, Philipp Wittmann, Andrea Milde, Till Pfister, Stefan M von Deimling, Andreas
...
Published in
Neuro-oncology
The international, multicenter registry LOGGIC Core BioClinical Data Bank aims to enhance the understanding of tumor biology in pediatric low-grade glioma (pLGG) and provide clinical and molecular data to support treatment decisions and interventional trial participation. Hence, the question arises whether implementation of RNA sequencing (RNA-Seq)...
Mule', Taylor N Hodges, Jason Wu, Shengjie Li, Yimei Ashford, Jason M Merchant, Thomas E Conklin, Heather M
Published in
Neuro-oncology
Social determinants of health including parental occupation, household income, and neighborhood environment are predictors of cognitive outcomes among healthy and ill children; however, few pediatric oncology studies have investigated this relationship. This study utilized the Economic Hardship Index (EHI) to measure neighborhood-level social and e...
Gross, Andrea M Dombi, Eva Wolters, Pamela L Baldwin, Andrea Dufek, Anne Herrera, Kailey Martin, Staci Derdak, Joanne Heisey, Kara S Whitcomb, Patricia M
...
Published in
Neuro-oncology
Selumetinib shrank inoperable symptomatic plexiform neurofibromas (PN) in children with neurofibromatosis type 1 (NF1) and provided clinical benefit for many in our previously published phase 1/2 clinical trials (SPRINT, NCT01362803). At the data cutoff (DCO) of the prior publications, 65% of participants were still receiving treatment. This report...
Ioakeim-Ioannidou, Myrsini Niemierko, Andrzej Kim, Daniel W Tejada, Athena Urell, Tobias Leahy, Shannon Adams, Judy Fullerton, Barbara Nielsen, G Petur Hung, Yin P
...
Published in
Neuro-oncology
Data on clinical outcomes for base of skull (BOS) chordomas in the pediatric population is limited. We report patient outcomes after surgery and proton radiotherapy (PRT). Pediatric patients with BOS chordomas were treated with PRT or combined proton/photon approach (proton-based; for most, 80% proton/20% photon) at the Massachusetts General Hospit...
Kim, Yeonju Armstrong, Terri S Gilbert, Mark R Celiku, Orieta
Published in
Neuro-oncology
Limitations in trial design, accrual, and data reporting impact efficient and reliable drug evaluation in cancer clinical trials. These concerns have been recognized in neuro-oncology but have not been comprehensively evaluated. We conducted a semi-automated survey of adult interventional neuro-oncology trials, examining design, interventions, outc...
Foss-Skiftesvik, Jon Li, Shaobo Rosenbaum, Adam Hagen, Christian Munch Stoltze, Ulrik Kristoffer Ljungqvist, Sally Hjalmars, Ulf Schmiegelow, Kjeld Morimoto, Libby de Smith, Adam J
...
Published in
Neuro-oncology
Although recent sequencing studies have revealed that 10% of childhood gliomas are caused by rare germline mutations, the role of common variants is undetermined and no genome-wide significant risk loci for pediatric central nervous system tumors have been identified to date. Meta-analysis of 3 population-based genome-wide association studies compr...
